PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Dexamethasone implants in paediatric patients with noninfectious intermediate or posterior uveitis: first prospective exploratory case series.

Abstract To evaluate the efficacy and safety of dexamethasone (DEX) implants in paediatric patients with noninfectious intermediate or posterior uveitis.
PMID
Related Publications

Efficacy of Ozurdex implant in treatment of noninfectious intermediate uveitis.

Treatment with repeat dexamethasone implants results in long-term disease control in eyes with noninfectious uveitis.

Outcome of Treating Pediatric Uveitis With Dexamethasone Implants.

Dexamethasone intravitreal implant (Ozurdex®) for pediatric uveitis.

Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis.

Authors

Mayor MeshTerms

Drug Implants

Keywords

Cataract

Dexamethasone implant

Glaucoma

Macular edema

Paediatric patients

Uveitis

Vitreous haze

Journal Title bmc ophthalmology
Publication Year Start




PMID- 29246154
OWN - NLM
STAT- MEDLINE
DCOM- 20180105
LR  - 20180105
IS  - 1471-2415 (Electronic)
IS  - 1471-2415 (Linking)
VI  - 17
IP  - 1
DP  - 2017 Dec 16
TI  - Dexamethasone implants in paediatric patients with noninfectious intermediate or 
      posterior uveitis: first prospective exploratory case series.
PG  - 252
LID - 10.1186/s12886-017-0648-3 [doi]
AB  - BACKGROUND: To evaluate the efficacy and safety of dexamethasone (DEX) implants
      in paediatric patients with noninfectious intermediate or posterior uveitis.
      METHODS: Prospective single center exploratory case series. Children and
      adolescents, 6 to 17 years old, with a vitreous haze score of >/=1.5+ or cystoid 
      macular edema (CME) of >300 mum were enrolled. Vitreous haze score at month 2 was
      chosen as primary endpoint. Best corrected visual acuity (BCVA), central retinal 
      thickness (CRT) and concomitant medication at month 6 were defined as secondary
      endpoints. Intraocular pressure (IOP) and cataract formation were determined as
      safety endpoints. RESULTS: Three out of 6 eligible patients participated in the
      case series. At month 2, vitreous haze was reduced from a score of 1.5+ to 0.5+
      and 0 and BCVA improved by >/=3 lines, >/=4 lines and >/=2 lines of Early
      Treatment of Diabetic Retinopathy (ETDRS)-letters, respectively. Visual acuity
      gain was accompanied by a CRT reduction of -186 mum and -83 mum in the first and 
      third patient, in whom CME was the indication for DEX implantation. A reduction
      of concomitant medication was achieved in 1 patient. IOP increase was seen in all
      3 patients, but could be treated sufficiently with primarily IOP lowering
      medications and without need for glaucoma surgery. Cataract progression did not
      occur. CONCLUSIONS: DEX implants led to an improvement in all endpoints,
      especially BCVA. This study confirms that IOP rises may also occur in the
      paediatric population and should be monitored and treated appropriately. TRIAL
      REGISTRATION: European Union Drug Regulating Authorities Clinical Trials
      (EudraCT)- nr: 2013-000541-39.
FAU - Winterhalter, Sibylle
AU  - Winterhalter S
AUID- ORCID: http://orcid.org/0000-0001-8509-5149
AD  - Department of Ophthalmology, Campus Virchow- Klinikum, Charite - University
      Medicine Berlin, corporate member of Freie Universitat Berlin, Humboldt-
      Universitat zu Berlin and Berlin Institute of Health, Berlin, Germany.
      [email protected]
FAU - Behrens, Uwe Diedrich
AU  - Behrens UD
AD  - Coordination Center for Clinical Studies, Campus Virchow- Klinikum, Charite -
      University Medicine Berlin, corporate member of Freie Universitat Berlin,
      Humboldt- Universitat zu Berlin and Berlin Institute of Health, Berlin, Germany.
FAU - Salchow, Daniel
AU  - Salchow D
AD  - Department of Ophthalmology, Campus Virchow- Klinikum, Charite - University
      Medicine Berlin, corporate member of Freie Universitat Berlin, Humboldt-
      Universitat zu Berlin and Berlin Institute of Health, Berlin, Germany.
FAU - Joussen, Antonia M
AU  - Joussen AM
AD  - Department of Ophthalmology, Campus Virchow- Klinikum, Charite - University
      Medicine Berlin, corporate member of Freie Universitat Berlin, Humboldt-
      Universitat zu Berlin and Berlin Institute of Health, Berlin, Germany.
FAU - Pleyer, Uwe
AU  - Pleyer U
AD  - Department of Ophthalmology, Campus Virchow- Klinikum, Charite - University
      Medicine Berlin, corporate member of Freie Universitat Berlin, Humboldt-
      Universitat zu Berlin and Berlin Institute of Health, Berlin, Germany.
LA  - eng
PT  - Journal Article
DEP - 20171216
PL  - England
TA  - BMC Ophthalmol
JT  - BMC ophthalmology
JID - 100967802
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Drug Implants)
RN  - 0 (Glucocorticoids)
RN  - 7S5I7G3JQL (Dexamethasone)
SB  - IM
MH  - Adolescent
MH  - Anti-Inflammatory Agents/*administration & dosage
MH  - Child
MH  - Delayed-Action Preparations/therapeutic use
MH  - Dexamethasone/*administration & dosage
MH  - *Drug Implants
MH  - Female
MH  - Glucocorticoids/*administration & dosage
MH  - Humans
MH  - Male
MH  - Prospective Studies
MH  - Uveitis, Intermediate/*drug therapy/pathology/physiopathology
MH  - Uveitis, Posterior/*drug therapy/pathology/physiopathology
MH  - Visual Acuity/physiology
MH  - Vitreous Body/pathology
PMC - PMC5732406
OTO - NOTNLM
OT  - Cataract
OT  - Dexamethasone implant
OT  - Glaucoma
OT  - Macular edema
OT  - Paediatric patients
OT  - Uveitis
OT  - Vitreous haze
EDAT- 2017/12/17 06:00
MHDA- 2018/01/06 06:00
CRDT- 2017/12/17 06:00
PHST- 2017/06/17 00:00 [received]
PHST- 2017/12/05 00:00 [accepted]
PHST- 2017/12/17 06:00 [entrez]
PHST- 2017/12/17 06:00 [pubmed]
PHST- 2018/01/06 06:00 [medline]
AID - 10.1186/s12886-017-0648-3 [doi]
AID - 10.1186/s12886-017-0648-3 [pii]
PST - epublish
SO  - BMC Ophthalmol. 2017 Dec 16;17(1):252. doi: 10.1186/s12886-017-0648-3.